PI3K p110δ inhibitors may also be effective in other forms of leukemia including acute myeloid leukemia [11] and in chronic myelomonocytic leukemia [46], where NOX2-dependent immunosuppression may occur. This evidence concerns the gene PIK3CD and chronic myelomonocytic leukemia.